Home › Compare › INFI vs RYLD

INFI vs RYLD: Dividend Comparison 2026

INFI yields 25000.00% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INFI wins by $481652020747103174656.00M in total portfolio value
10 years
INFI
INFI
● Live price
25000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$481652020747103174656.00M
Annual income
$477,891,679,681,809,340,000,000,000.00
Full INFI calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — INFI vs RYLD

📍 INFI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINFIRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INFI + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
INFI pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INFI
Annual income on $10K today (after 15% tax)
$2,125,000.00/yr
After 10yr DRIP, annual income (after tax)
$406,207,927,729,537,960,000,000,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, INFI beats the other by $406,207,927,729,537,960,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INFI + RYLD for your $10,000?

INFI: 50%RYLD: 50%
100% RYLD50/50100% INFI
Portfolio after 10yr
$240826010373551587328.00M
Annual income
$238,945,839,840,904,670,000,000,000.00/yr
Blended yield
99.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on INFI right now

INFI
Analyst Ratings
8
Buy
9
Hold
Consensus: Hold
Altman Z
-63.6
Piotroski
3/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INFI buys
0
RYLD buys
0
No recent congressional trades found for INFI or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINFIRYLD
Forward yield25000.00% ✓12.14%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$481652020747103174656.00M ✓$44.5K
Annual income after 10y$477,891,679,681,809,340,000,000,000.00 ✓$2,587.35
Total dividends collected$481404327977371041792.00M ✓$18.8K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: INFI vs RYLD ($10,000, DRIP)

YearINFI PortfolioINFI Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$2,510,700$2,500,000.00$11,914$1,213.65+$2.50M → INFI
2$589,298,599$586,612,149.53$14,099$1,351.30+$589.28M → INFI
3$129,309,604,119$128,679,054,618.90$16,580$1,494.55+$129309.59M → INFI
4$26,527,150,102,459$26,388,788,826,051.22$19,384$1,642.61+$26527150.08M → INFI
5$5,087,743,001,217,608$5,059,358,950,607,977.00$22,535$1,794.70+$5087743001.20M → INFI
6$912,316,496,169,531,500$906,872,611,158,228,600.00$26,063$1,950.00+$912316496169.51M → INFI
7$152,954,929,371,424,950,000$151,978,750,720,523,570,000.00$29,995$2,107.69+$152954929371424.91M → INFI
8$23,976,822,470,935,107,000,000$23,813,160,696,507,682,000,000.00$34,361$2,266.99+$23976822470935108.00M → INFI
9$3,514,337,444,199,857,700,000,000$3,488,682,244,155,957,000,000,000.00$39,194$2,427.12+$3514337444199857664.00M → INFI
10$481,652,020,747,103,200,000,000,000$477,891,679,681,809,340,000,000,000.00$44,525$2,587.35+$481652020747103174656.00M → INFI

INFI vs RYLD: Complete Analysis 2026

INFI — Stock

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

Full INFI Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this INFI vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INFI vs SCHDINFI vs JEPIINFI vs OINFI vs KOINFI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.